There are still lots of open positions. Let's find the one that's right for you.
Sarepta is at the forefront of genetic medicine, holding leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). With over 40 programs in various stages of development in gene therapy, RNA, and gene editing, we launched our fourth therapy in 2023, marking the first-ever gene therapy to treat Duchenne. This position will report to the Director of Gene Therapy Manufacturing and will be responsible for overseeing all aspects of manufacturing at the CMO to ensure clinical and commercial drug supply needs are met.